Exchange: NASDAQ·Updated 07:30 PM EDT

HTFL News

News
all
press releases
HeartFlow's CEO Sells 38,900 Shares for $1.8 Million After the Stock Hit a 52-Week High
Key PointsThe transaction involved 38,900 shares valued at ~$1.8 million based on a weighted average price of $46.78 per share...
Nasdaq News: Markets
HeartFlow's CEO Sells 38,900 Shares for $1.8 Million After the Stock Hit a 52-Week High
Key PointsThe transaction involved 38,900 shares valued at ~$1.8 million based on a weighted average price of $46.78 per share...
Nasdaq News: Markets
More News
HeartFlow CFO Dumps Over 33,000 Shares for $1.7 Million as the Stock Hits a 52-Week High
Key PointsThe sale of 33,416 shares generated a total value of approximately $1.7 million based on a weighted average execution price of $49.85...
Nasdaq News: Markets
HeartFlow's Chief Medical Officer Sells 9,219 Shares Amid a Soaring Stock Price. What Does That Mean for Investors?
Key PointsThe executive sold 9,219 shares at $41.23 per share on August 17, 2026, generating ~$380,100...
Nasdaq News: Markets
Why Heartflow Stock Soared Today
Key PointsHeartflow's AI-powered platform could save countless lives...
Nasdaq News: Markets
HeartFlow Shares Soar Following Strong Q2 Results and Upgraded Guidance
HeartFlow shares are surging Friday after it reported better-than-expected Q2 adjusted EPS results and raised its full-year outlook.read more...
Benzinga
Heartflow, Eton Pharmaceuticals, Nu Holdings And Other Big Stocks Moving Higher On Friday
U.S. stocks up, Dow Jones 0.1% higher. HeartFlow (HTFL) shares rise 26.5% on better-than-expected earnings. Other big gains include ETON, VALN, IMXI.read more...
Benzinga
HeartFlow Q2 2026 Earnings Call Transcript
HeartFlow (NASDAQ:HTFL) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access toread more...
Benzinga
HeartFlow (HTFL) Reports Q2 Loss, Beats Revenue Estimates
HeartFlow (HTFL) delivered earnings and revenue surprises of +50.00% and +12.96%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates
Stereotaxis (STXS) delivered earnings and revenue surprises of -66.67% and -19.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Doximity (DOCS) Q1 Earnings Lag Estimates
Doximity (DOCS) delivered earnings and revenue surprises of -3.33% and +3.24%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.